Exhibit 10.21
[SOSEI LOGO]
SOSEI CO., LTD.
KOUJIMACHI N K XXXX. 0-00-0, XXXXXXXXXX
XXXXXXX-XX, XXXXX 000-0000, XXXXX
TEL: x00-(0)0-0000-0000
FAX: x00-(0)0-0000-0000
Tokyo, September 17, 2003
CombinatoRx Incorporated
000 Xxxxxx Xxxxxx
Xxxxxx, XX 00000
U. S. A.
Dear Sirs,
This letter agreement will serve to confirm our mutual understanding regarding
the Material Testing Agreement dated April 18, 2002 entered into between us (the
"MTA").
1. As from September 17, 2003, the Compounds which Sosei provides to
CombinatoRx and on which CombinatoRx carries out the screening will be
limited to the DRP Compounds; provided that CombinatoRx shall continue to
conduct, and complete the screening of the DRPM Compounds already supplied
by Sosei (of which list is attached to this letter), and the conditions for
such screening and the results and the discoveries obtained therefrom shall
be subject to the terms of the MTA in all respects.
2. Except as provided for in 1. above, the terms of the MTA remain
unchanged.
If the foregoing is acceptable to you, please so indicate by signing the
duplicate copy of this letter in the space provided below and returning it to
us; whereupon it shall constitute a binding agreement between you and us.
With best regards,
/s/ Xxxx Xxxxxx
----------------------------------
Xxxx Xxxxxx, Ph.D.
Representative Director, EVP R&D
Sosei Co., Ltd.
Agreed and Accepted by:
CombinatoRx Incorporated
/s/ Xxxxxx Xxxx
---------------------------------------
Xxxxxx Xxxx
Vice President
Corporate Development and Strategy
CombinatoRx, Incorporated
